Shots:
- Acesion Pharma has enrolled the first patients in the P-II trial assessing AP31969 in pts with atrial fibrillation, with completion anticipated by Q1’27
- Trial will enrol 200 pts across eight EU countries, with AF burden as the 1EP. Safety will be monitored using implantable loop recorders for continuous 24/7 cardiac rhythm tracking
- In 2025, Acesion completed a P-I trial of AP31969 in 92 healthy volunteers (SAD & MAD), showing a favorable safety profile, suitable PK for chronic oral use, & no clinically relevant effects on QTc, supporting minimal proarrhythmia risk
Ref: PRnewswire | Image: Acesion Pharma | Press Release
Related News: Incyte Reports the Topline P-III (frontMIND) Trial Data on Monjuvi (Tafasitamab) Combination for Diffuse Large B-Cell Lymphoma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
